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Abstract: The surface properties of nanoparticles have decisive influence on their interaction with
biological barriers (i.e., living cells), being the concentration and type of surfactant factors to have
into account. As a result of different molecular structure, charge, and degree of lipophilicity,
different surfactants may interact differently with the cell membrane exhibiting different degrees
of cytotoxicity. In this work, the cytotoxicity of two cationic solid lipid nanoparticles (SLNs),
differing in the cationic lipids used as surfactants CTAB (cetyltrimethylammonium bromide) or DDAB
(dimethyldioctadecylammonium bromide), referred as CTAB-SLNs and DDAB-SLNs, respectively,
was assessed against five different human cell lines (Caco-2, HepG2, MCF-7, SV-80, and Y-79). Results
showed that the cationic lipids used in SLN production highly influenced the cytotoxic profile of
the particles, with CTAB-SLNs being highly cytotoxic even at low concentrations (IC50 < 10 µg/mL,
expressed as CTAB amount). DDAB-SLNs produced much lower cytotoxicity, even at longer exposure
time (IC50 from 284.06 ± 17.01 µg/mL (SV-80) to 869.88 ± 62.45 µg/mL (MCF-7), at 48 h). To the
best of our knowledge, this is the first report that compares the cytotoxic profile of CTAB-SLNs and
DDAB-SLNs based on the concentration and time of exposure, using different cell lines. In conclusion,
the choice of the right surfactant for biological applications influences the biocompatibility of
the nanoparticles. Regardless the type of drug delivery system, not only the cytotoxicity of the
drug-loaded nanoparticles should be assessed, but also the blank (non-loaded) nanoparticles as their
surface properties play a decisive role both in vitro and in vivo.
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1. Introduction
Solid lipid nanoparticles (LNs) were developed in the 1990s and were proposed as an alternative
to traditional carriers (e.g., polymeric nanoparticles, liposomes). Since then SLNs have been receiving
the attention of researchers from both academia and industry for a set of applications [1,2]. Solid
lipid nanoparticles (SLNs) are colloidal carriers composed of a lipid matrix that is solid at body and
room temperature (i.e., of melting point above 40 ◦C), and stabilized by appropriate surfactants [2,3].
In the last years, efforts have been made to develop SLN formulations with distinctive properties, e.g.,
capacity to improve the solubility of poorly water-soluble drugs and consequently their bioavailability,
to enhance their targeting potential and cellular uptake, as well as their biological compatibility. SLNs
are regarded as carriers with reduced toxicity [2–4], and have become popular in several areas, aiming
to physicochemically protect the loaded drugs and to minimize their side-effects. In this regard, the
components of nanoparticles aiming to deliver pharmaceutically active substances by routes, such
as intravenous, oral, nasal pulmonary, must be of high grade and biocompatible to physiological
systems. Other features to consider are the physicochemical properties of nanoparticles that influence
stability and shelf-life of formulations, which can be improved by selecting the appropriate lipids and
surfactants in the right combinations [2,5–7]. Surfactants are used to disperse the solid–lipid matrix in
water thereby reducing the surface tension and energy to control the shape and prevent the risk of
nanoparticles’ aggregation under shelf life [6,8,9].
Surfactants are defined as molecules with amphiphilic/amphipathic properties, having separate
hydrophobic or solvophobic groups and hydrophylic or solvophilic properties. This feature arises from
the chemical structure that consists of both a typically long alkyl chain (non-polar or hydrophobic groups,
being named as “tails”) and a polar or hydrophilic group (named as “heads”) [10,11]. Surfactants are
characterized by the presence or absence of charged groups in the head portion, being classified as ionic
and non-ionic, respectively [9,10]. Depending on the total charge in the head group, ionic surfactants
are further classified as (i) cationic, if positively charged, (ii) anionic, if negatively charged, and (iii)
amphoteric, if presenting both a positive and a negative charge [11–13]. The behavior of amphoteric
surfactants is pH-dependent, being able of depicting a net positive charge (cationic) at low pH, a net
negative charge (anionic) at high pH, and null net charge (zwitterionic) at intermediate pH values [13].
Surfactants have been used for a wide range of industrial applications in different sectors, e.g., foods,
cosmetics, pharmaceuticals, with emphasis in the production of micro and nanoparticles [14]. The
positive surface charge provided by the use of cationic surfactants may improve the cell–particle
interaction as SLNs are attracted by the negatively charged membrane phospholipid. If negatively
charged, such interaction is prevented or restrained.
However, the interaction of cationic SLNs with the cells may be followed by some degree
of toxicity. Indeed, it has been documented that non-ionic surfactants are less toxic, than ionic
surfactants [3,15], while cationic surfactants have been reported to produce higher toxicity, as a
result of their higher interaction with cell membranes [3,14,16]. Among cationic surfactants, CTAB
(cetyltrimethylammonium bromide) and DDAB (dimethyldioctadecylammonium bromide) have been
used in various industrial processes (e.g., as biocides and antiseptic agents [17]), and in the production
of drug-loaded nanoparticles for various applications [4,18–23]. While CTAB has a single chain and a
single positive charged head-group, DDAB on the other hand is a double chain cationic lipid showing
higher lipophilicity [24]. Because of these structural differences, CTAB and DDAB exhibit distinct
capacity to interact and to disturb the plasmatic membrane of cells. Thus, the comparison of their
toxicity under the same conditions is crucial for the selection of the less cytotoxic when designing SLNs
for different administration routes and cell targets.
The aim of this work is to compare the in vitro biocompatibility of two types of SLNs differing
in their cationic lipid composition (i.e., surface-tailored either with CTAB or with DDAB). To this
aim, five different human cell lines were used: Caco-2 (epithelial colorectal adenocarcinoma), HepG2
(liver hepatocellular carcinoma), SV-80 (lung fibroblast), MCF-7 (breast adenocarcinoma), and Y-79
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(human retinoblastoma), mimicking several administration routes, for which a set of concentrations
have been selected.
2. Materials and Methods
2.1. Materials
CTAB (cetyltrimethylammonium bromide; MW 364.45 g/mol, CAS Number: 57-09-0) was
purchased from Sigma-Aldrich (Sintra, Portugal). DDAB (dimethyldioctadecylammonium bromide;
MW 630.95 g/mol; CAS Number: 3700-67-2) was obtained from Avanti Polar Lipids (Alabama, USA).
Softisan®100 (S100) was a gift from Sasol Germany GmbH (Witten, Germany), Lipoid® S75, composed
of 75% soybean phosphatidylcholine was acquired from Lipoid GmbH (Ludwigshafen, Germany),
Lutrol®F68 or Poloxamer 188 (P188) was a gift from BASF (Ludwigshafen, Germany). Anhydrous
glycerol was acquired from Acopharma (Barcelona, Spain). In all assays ultra-pure water was used
and obtained from a MiliQ Plus system (Millipore, Germany).
Other reagents and salts, not mentioned, were of high purity and were acquired from Sigma-Aldrich
(Sintra, Portugal).
2.2. Cationic SLNs Production
Cationic SLNs were produced as previously reported by us [4,24,25], using the multiple emulsion
(w/o/w) technique. This method produces SLNs of spherical shape, as reported by Fangueiro et al. [4].
Briefly, the lipid phase was composed of (in wt %): glycerol (37.5), Sofitsan S100 (4.5), Lipoid S75
(0.5), cationic lipid (0.5 CTAB or 0.5 DDAB). A volume (1.25 mL) of ultra-pure water was added to the
lipid phase at the same temperature (5 ◦C to 10 ◦C above the melting point of lipid S100) and then
homogenized (60 s, sonication probe diameter = 6 mm) using an ultrasonic processor VCX500 (Sonics,
Switzerland). A power output, using an amplitude of 40%, was applied. The solution of poloxamer
(1.0 wt%) was added and the mixture was then homogenized for 90 s. This pre-emulsion was then
poured in the total volume of poloxamer-cooled solution under magnetic stirring for 15 min to allow
the SLN formation (formulation total volume = 20 mL). The obtained SLNs dispersions were used for
subsequent studies.
2.3. Physicochemical Characterization
Dynamic light scattering (DLS, Zetasizer Nano ZS, Malvern Instruments, Malvern, UK) was used
to determine the physical parameters: mean particle size (Z-Ave) and polydispersity index (PI). All
samples, diluted with ultra-purified water to suitable concentration, were analyzed in triplicate. Zeta
potential (ZP) was also determined in ultra-purified water with the conductivity adjusted to 50 µS/cm
(using NaCl solution at 0.9%, w/V) to avoid ionic effects. Laser diffraction (LD) was performed also for
particle size analysis using a Mastersizer Hydro 2000 MU (Malvern Instruments, Malvern, UK).
2.4. Cell Culture and Viability Assay
Cell culture and maintenance: Caco-2 (human epithelial colorectal adenocarcinoma), HepG2
(human liver hepatocellular carcinoma), and SV-80 (human lung fibroblast) cells were maintained in
DMEM (Dulbecco’s Modified Eagle Medium), MCF-7 (human breast adenocarcinoma) in DMEM/F12
(Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12), and Y-79 (human retina retinoblastoma)
in RPMI-1640 (Roswell Park Memorial Institute (RPMI) 1640 medium), supplemented with 10% (v/v)
fetal bovine serum (FBS), 2 mM l-glutamine, and antibiotics (100 U/mL penicillin and 100 µg/mL of
streptomycin) in an atmosphere of 5% CO2 in air, at 37 ◦C with controlled humidity. Cell lines: Caco-2,
SV-80, and Y-79 were acquired from Cell Lines Service (CLS, Eppelheim, Germany), HepG2 and MCF-7
were acquired from ATCC (ATCC, Rockville, MD, USA). All cell culture media and supplements were
from Gibco (Alfagene, Lisbon, Portugal).
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Cell preparation prior to cytotoxicity assays: Confluent cells were subjected to trypsin treatment
(except Y-79, which grows in suspension), as described [26]. Briefly, after trypsinization, cells were
counted, diluted in culture media to achieve a density of 5 × 104 cells/mL and then were plated in
96-well plates (100 µL/well). Cells were further cultured, for at least 24 h, to allow cell adherence
and reestablishment of growth. Y-79 cells were aspirated from growing flasks using a serological
pipette, placed in 15-mL sterile centrifuge tube and then centrifuged (to eliminate the supernatant).
The pellet containing the cells was re-suspended in fresh culture media; as these cells form clusters.
The cell cluster disaggregation was performed by applying gentle aspirations with a Pasteur pipette.
After re-suspension and disaggregation, cells were counted, diluted to a density of 1 × 105 cells/mL, in
culture media, and then were seeded in 96-well plates pre-coated with poly-L-lysine (100 µL/well, i.e.,
1 × 104 cells/well). Cells were left in culture for at least 24 h to allow cell adherence.
Cytotoxicity/viability assay: Two different LNs formulations: CTAB-SLNs and DDAB-SLNs were
assayed for cytotoxicity, at four concentrations, calculated as surfactant (CTAB or DDAB) concentration
in the formulation, in µg mL−1: 66.0, 165.0, 330.0, and 660.0. Test solutions were prepared just prior to
cell application, by dispersing the required volume of particles in FBS-free culture media to achieve the
desired final concentration. Test solutions (100 µL/well; in quadruplicates) were added to the cells,
after removing the growing culture media, and cells were exposed for 24 h or 48 h to test solutions
before the cell viability assessment using the Alamar Blue (Invitrogen; Alfagene, Lisbon, Portugal), as
previously reported [27,28]. Briefly, 24 h or 48 h after cell exposure, the incubating test solutions were
removed and replaced by Alamar Blue solution (10% (v/v) in FBS-free culture media; 100 µL/well). The
absorbances, at 570 and 620 nm (reduced and oxidative form or resazurin, respectively [22]) were read
~5 h after the addition of Alamar Blue solution. Data were analyzed by calculating the percentage
of Alamar blue reduction (using the equations and procedures as previously reported [4,26,27]) and
results were expressed as percentage of control (untreated cells).
Determination of IC50: The IC50 (half maximal inhibitory concentration or concentration that
inhibits 50% of cell viability/proliferation) was calculated as reported by Silva et al. [25], from
each individual dose-response experiment using Excel or GraphPad Prism tolls (n = 3 independent
experiments; each experiment in quadruplicate). Each individual data was plotted as % cell viability
(y-axis) vs. concentration (x-axis), fitted to a non-linear regression (logarithmic fitting; Y = a ln(X)± c),
and the IC50 values were calculated from obtained equations, making Y = 50% and obtaining the
corresponding X value, which gives the concentration that produces 50% viability. For each individual
data-set, the R2 values were between 0.85 and 0.99. The IC50′ values are indicated as the mean ± S.D.
of IC50′ calculated from three independent experiments, performed for each cell line and for each
exposure time (24 or 48 h).
2.5. Statistical Analysis
Statistical significance of cell viability results was determined using two-way analysis of variance
(ANOVA), followed by Tukey multiple comparison test using 95% of confidence, i.e., obtained p-value
< 0.05 was set as significant between groups. Also, multiple t-test, using the Bonferroni–Dunn method
(95% confidence) was used when needed. Data were expressed as mean value ± standard deviation
(mean ± SD) of n experiments, as indicated.
3. Results and Discussion
3.1. SLNs Production and Characteristics
SLNs production was performed using the multiple emulsion (w/o/w) technique, as previously
reported [4]. DLS analysis indicated that the particles size was under 150 nm, with a relatively
narrow distribution (<0.25), as shown in Table 1. These SLN present relatively high positive ZP values
(~+28 mV), which is achieved because of the use of cationic lipids, CTAB and DDAB as surfactants.
The strategic use of CTAB and DDAB, aimed the improvement of the particles’ stability as a result of
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repulsion between positive surface charges, which is responsible for a reduction in particle aggregation
and posterior dynamic changes in particle size. The interaction between particles and cells is favored
by the positive charges at particles surface, as cells present a negative surface charge, which is a point
in favor to improve the delivery of encapsulated material [3]. But, on the other hand, the increased
interaction of nanoparticles with cells also may alter the cell membrane stability, resulting in cytotoxicity.
Indeed, a previous work demonstrated that CTAB, in a dose-dependent fashion, was an important
contributor to cell cytotoxicity [4]. Laser diffraction results also showed that the mean particle size of
these SLN was within the nanometer range, from 118 nm to 120 nm, as shown in Table 1. These results,
i.e., surface charge and mean particle size, may contribute to improve the adhesion of SLNs to the
cell membrane and their internalization to release the drug inside cells. These interactions may also
interfere with cell metabolism and lead to toxicity. CTAB and DDAB have been selected as cationic
surfactants for the production of CTAB-SLNs and DDAB-SLNs, respectively, as they are commonly
used in the production of cationic nanoparticles.
Table 1. Mean particle size (Z-Ave), polydispersity index (PI), and zeta potential (ZP) of solid lipid
nanoparticles (SLNs), recorded by dynamic light scattering (DLS), and d50% measured by laser
diffraction (LD). Results are indicated as mean ± S.D. (n = 3).
Formulation
DLS LD
Z-Ave (nm) PI ZP (mV) d50 (nm)
CTAB-SLNs 135.1 ± 0.22 0.196 ± 0.02 +28.20 ± 1.33 118.3 ± 0.04
DDAB-SLNs 134.2 ± 1.12 0.179 ± 0.07 +28.20 ± 2.29 119.8 ± 0.01
3.2. Assessment of CTAB and DDAB-Decorated SLNs Cytotoxicity
Different cell lines were exposed to different concentrations of CTAB-SLNs and DDAB-SLNs, as
shown in Table 2. The wt%, as concentration unit, is commonly used as a parameter in nanoparticles
production. As these two surfactants have different molecular weights, Table 2 also shows the
concentration (in µM) of surfactants in SLNs.
Table 2. CTAB (cetyltrimethylammonium bromide) and DDAB (dimethyldioctadecylammonium
bromide) concentrations of each test solution (in µg/mL and in µM) used in this study. See methods for
details (wt% of CTAB and DDABB (g/100 mL) in formulation was 0.5).
CTAB (*) µg/mL 66.0 165.0 330.0 660.0
µM 181.1 452.7 905.5 1810.9
DDAB (*) µg/mL 66.0 165.0 330.0 660.0
µM 104.6 261.5 523.0 1046.0
(*), not present in the same formulation.
Figure 1 shows the effect of exposure to CTAB-SLNs and DDAB-SLNs in the different cell lines.
CTAB-SLNs produced a drastic decrease of cell viability to values close to zero in all cell lines (Figure 1),
which is translated by the low IC50 (Table 3) calculated for 24 and 48 h of exposure. For all cell lines, IC50
was <10 µg/mL in both exposure times. In a study using Y-79 cells, Fangueiro et al. [4] demonstrated
that the concentration of CTAB compromises the cell viability at concentrations above 0.5% (wt%) [4].
However, CTAB concentration is critical for the mean particle size. Indeed, that the mean particle size
decreases with the increase of CTAB concentration (239.5 ± 0.61 nm to 144.7 ± 1.61 nm, at 0.25 and
1.0% (wt%), respectively [4]). The increase of CTAB concentration also increased the ZP of SLNs, from
+24 mV (at 0.25%) to +48 mV (at 1.0%) favoring the particles’ stability and their interactions with the
cells [4].
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Figure 1. Cell viability profiles of CTAB-SLNs and DDAB-SLNs in Caco-2 (A), HepG2 (B), MCF-7 (C), 
SV-80 (D), and Y-79 (E) cells. Cells were exposed to CTAB-SLNs and DDAB-SLNs test solution, 
indicated in µg/mL of surfactant in test solution (66.0, 165.0, 330.0, and 660.0), for 24 h. Results, 
expressed as % of control (non-exposed cells), indicate the mean ± SD of n = 3 independent 
experiments (see methods). * Indicates statistical significance (p < 0.05) between control and different 
concentrations, for each condition (CTAB-SLNs and DDAB-SLNs). Statistical significance (p < 0.05) 
between the effect of DDAB-SLNs and CTAB-SLNs, at same concentration, was found to all values 
(not indicated). 
Table 3. IC50 values calculated for each cell line exposed to CTAB-SLNs and DDAB-SLNs for 24 or 48 
h (as indicated). Values represent the mean ± S.D. (see methods for details). 
Cell Line Time 
IC50 (µg/mL) * 
CTAB-SLNs DDAB-SLNs 
Caco-2 24 h 8.91 ± 0.020 983.99 ± 97.01 
48 h 8.72 ± 0.119 845.20 ± 54.98 
HepG2 
24 h 9.70 ± 0.158 510.25 ± 18.10 
48 h 9.04 ± 0.026 343.53 ± 10.56 
MCF-7 
24 h 8.91 ± 0.099 1121.14 ± 104.28 
48 h 9.11 ± 0.099 869.88 ± 62.45 
SV-80 
24 h 9.31 ± 0.079 594.06 ± 16.43 
48 h 8.91 ± 0.152 284.06 ± 17.01 
Y-79 
24 h 8.72 ± 0.059 1015.28 ± 39.50 
48 h 9.24 ± 0.059 540.21 ± 10.49 
* Values given in µg/mL of CTAB or DDAB in formulation. 
The results from cytotoxicity and IC50 suggest that the choice of surfactant is relevant when 
designing formulations aiming the direct contact with the cells (i.e., intravenous injections or mucosal 
application), and thus caution has to be taken concerning the final concentration of CTAB. 
Wang et al. produced gold nanoparticles (Au-NRs or nanorods) stabilized with CTAB [29]. The 
cytotoxic effect of both Au-NRs and CTAB was assessed against keratinocytes. The authors reported 
that the inherent toxicity of Au-NRs was mainly due to the presence of the cationic surfactant. CTAB 
decreased the cell viability at concentrations as low as 10 µM (or 3.64 µg/mL) [29], a value within the 
same range of concentrations here reported for CTAB-SLNs (Figure 1, Table 2). For some time, the 
Figure 1. Cell viability profiles of CTAB-SLNs and DDAB-SLNs in Caco-2 (A), HepG2 (B), MCF-7
(C), SV-80 (D), and Y-79 (E) cells. Cells were exposed to CTAB-SLNs and DDAB-SLNs test solution,
indicated in µg/mL of surfactant in test solution (66.0, 165.0, 330.0, and 660.0), for 24 h. Results,
expressed as % of control (non-exposed cells), indicate the mean ± SD of n = 3 independent experiments
(see methods). * Indicates statistical significance (p < 0.05) between control and different concentrations,
for each condition (CTAB-SLNs and DDAB-SLNs). Statistical significance (p < 0.05) between the effect
of DDAB-SLNs and CTAB-SLNs, at same concentration, was found to all values (not indicated).
Table 3. IC50 values calculated for e ch cell line exposed to CTAB-SLNs and DDAB-SLNs for 24 or 48 h
(as indicated). Values represent the mean ± S.D. (see methods for details).
Cell Line Time
IC50 (µg/mL) *
CTAB-SLNs DDAB-SLNs
Caco-2
24 h 8.91 ± 0.020 983.99 ± 97.01
48 h 8.72 ± 0.119 845.20 ± 54.98
HepG2 24 h 9.70 ± 0.158 510.25 ± 8.10
48 h 9.04 ± 0.026 343.53 ± 10.56
MCF-7
24 h 8.91 ± 0.099 1121.14 ± 104.28
48 h 9.11 ± 0.099 869.88 ± 2.45
SV-80
24 h 9.31 ± 0.079 594.06 ± 16.43
48 h 8.91 ± 0.152 2 4.0 ± 17.01
Y-79
24 h 8.72 ± 0.059 1015.28 ± 39.50
48 h 9.24 ± 0.059 540.2 ± 0.49
* Values given in µg/mL of CTAB or DDAB in formulation.
The results from cytotoxicity and IC 0 suggest that the choice of surfactant is relevant when
designing formulations aiming the direct contact ith the cells (i.e., intravenous injections or mucosal
application), and thus caution has t t cerning the final concentration of CTAB.
Wang et al. roduced gold anoparticles (Au-NRs or nanorods) stabilized with CTAB [29].
The cytotoxic effect of both Au-NRs and CTAB was assessed ag i st keratinocytes. The authors
reported that the inherent toxicity of Au-NRs was mainly due to th pres nce f the cationic surfactant.
CTAB decreased the cell vi bility at concentrations as low as 10 µM (or 3.64 µg/mL) [29], a value
within the same range of concentrations here reported for CTAB-SLNs (Figure 1, Table 2). For some
time, the toxicity of Au-NRs was attributed to the particle shape, but Qiu et al. [30] described that
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the toxicity was due to both the CTAB molecules surfacing Au-NRs and to those that were left in
the suspended solution. CTAB molecules permeate cell membranes, enter the cell and damage the
mitochondria resulting in depolarization, increased reactive oxygen species (ROS), and apoptosis.
High and dose-dependent intracellular concentration of ROS was observed in HepG2 cells, either
exposed to SLNs (containing CTAB as surfactant) or to CTAB alone, triggering oxidative stress and
resulting in activation of intracellular antioxidant enzymes system [19].
The cytotoxicity of CTAB in human keratinocytes (HaCaT) and osteoblast-like (SAOS-2) cell lines,
in the presence or absence of serum (FBS), was shown to be CTAB dose-dependent and was affected
by the presence of FBS which clearly showed cell protection [15]. In the absence of FBS (the same
conditions in which our incubations were performed), 200 µM (72.88 µg/mL) of surfactant reduced the
metabolic activity of cells (SAOS-2 to ~20% and HaCaT to less than 10%), although in live/dead assays,
at 200 µM only a slight decrease in SAOS-2 cells viability was observed [15]. Although the metabolic
activity is low, the percentage of dead cells is still low, suggesting that, after 24 h incubation, cells still
trigger the apoptotic events.
On the other hand, DDAB-SLNs produced very low toxicity when compared to CTAB-SLNs
(Figure 1 and Table 3), the cell viability being higher than 90% of control (for all tested cell lines),
at 165 µg/mL DDAB (or, 261.51 µM; see Table 2), and higher than 50% for twice this concentration
(330 µg/mL; also for all cell lines). On average, cell viability was still above 50% for Caco-2 (Figure 1A),
MCF-7 (Figure 1C), and Y-79 (Figure 1E) cells exposed to 660 µg/mL DDAB-SLNs. While all cell lines
are highly and equally affected by CTAB-SLNs (IC50 < 10 µg/mL; identical to all cell lines), the effect
of DDAB-SLNs is cell line-dependent, and shows an order of potency (at 24 h exposure): HepG2 >
SV-80 > Caco-2 > Y-79 > MCF-7, the IC50 obtained for HepG2 and MCF-7 exposure to DDAB-NPs
being ~50-fold and ~130-fold, respectively, higher than for CTAB-NPs exposure (Table 3). These results
translate a higher safety profile of DDAB when compared to CTAB.
The effect of different sets of SLNs containing different concentrations of DDAB was tested in
colorectal carcinoma (HCT-116) and bronchial epithelial (16-HBE) human cell lines [7], showing that at
the highest tested SLN concentration (500 µg/mL, ~40 µg/mL of DDAB), the loss of cell viability was
~20% for both cell lines. These concentrations are significantly lower than those tested in our work
(Figure 1), showing that toxicity might also be dependent on the other components of the formulation
(Precirol ATO 5 and the surfactants Brij 76 [7]) and/or of the cell line. The IC50 values reported by
Botto et al. [7], together with the observed low toxicity, is in line with our results. The effect of
DDAB in solution was assessed in 29 human and non-human cell lines, showing a cell-dependent
toxicity, the Neuro2a (mouse neuroblastoma; EC50 = 0.64 µM; 0.40 µg/mL) being the most affected with
U-937 (Human leukemia; EC50 = 2.12 µM; 1.33 µg/mL) and, the MDCK (dog kidney; EC50 = 21.4 µM;
13.50 µg/mL) the least affected [31]. In this set of cells, A-172 (human glioblastoma; EC50 = 15 µM;
9.46 µg/mL), Caco-2, HepG2, and MCF-7 showed EC50′s of 11.4 ± 1.14, 13.4 ± 0.80, and 9.63 ± 4.11,
respectively [31], indicating that nanoparticles are less toxic than the individual counterparts. Kusumoto
and Ishikawa [31] attributed cytotoxicity of DDAB to the formation of pores in cell membrane leading
to apoptotic events, either intrinsic or extrinsic.
Other important and distinctive characteristic of these two surfactants is the critical micellar
concentration (CMC; defined as the minimal concentration of surfactants that induces the spontaneous
formation of micelles) [32,33], which is ~1 mM to CTAB [34] and ~14 mM to DDAB [35]. It has been
reported that cell viability decrease and cell lysis only occur at or near the CMC of the surfactant [36],
therefore the lowest tested CTAB and DDAB concentrations were ~5-fold and 134-fold lower than the
respective CMC. For this reason, we have observed a higher toxicity for CTAB as the used concentration
is closer to the CMC.
In order to counteract the surfactant-induced toxicity, a preventive measure is to decrease the
concentration of free/unbound surfactant in nanoparticles suspension by, e.g., centrifugation as
described by Wang et al. [29]. However, this method does not prevent the CTAB-induced damage, as
CTAB may eventually unbind from the nanoparticles [29,37]. Other strategies include the application
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of a coat to the surfactant layer, creating a barrier between the nanoparticle and the cell membrane,
thereby preventing the toxic interaction. This coating can be made of several components, such as
proteins (e.g., BSA), polyelectrolytes (e.g., polystyrene sulfonate), or silica [37].
With the results here discussed, one should always have in mind that the components of SLNs
might be as toxic as the encapsulated drugs. Thus, if not previously assessed adequately, the non-specific
damage caused by SLNs components might be higher than the desired therapeutic effect. Thus, not
only the cytotoxicity of the drug-loaded SLNs should be assessed, but also the blank (non-loaded)
SLNs as their surface properties play a decisive role both in vitro and in vivo.
4. Conclusions
SLNs require the use of surfactants to stabilize the size and charge in order to improve stability
in suspension as well as cell internalization. However, some stabilizers may damage cells by direct
interference with cell membrane integrity. In this work, CTAB was shown to be highly toxic compared
to DDAB at the same concentration. All cell lines reduced their viability to values near zero in the
presence of CTAB (IC50 < 10 µg/mL), while DDAB-SLNs produced IC50 values that were about 50-fold
(HepG2) to 180-fold (MCF-7) higher than CTAB-SLNs, indicating the much lower toxicity of DDAB
(Table 3). Thus, DDAB is tolerated by cells, while CTAB is highly toxic. One must bear in mind that
these cells, used in in vitro assays, have no protection against membrane damaging agents. The same
does not occur in vivo as other defense mechanisms may be active. Likewise, in dermal application
the outer epidermal layer may protect the lower skin layers and the presence of connective tissue may
act as a buffer to these agents, reducing the in vivo toxicity.
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